JAZZ News and Press, Jazz Pharmaceuticals plc From 02/09/23

Cannabis stocks rose to prominence a few years ago when Canada famously legalized the recreational use of pot. And although some of that initial excitement has died down, there is no question that the industry still presents a lucrative opportunity for long-term investors. According to some estim...

Cannabis stocks had a rough time over the past year, with the EFT Alternative Harvest ETF (NYSEMKT: MJ) and the AdvisorShares Pure Cannabis ETF (NYSEMKT: YOLO) down by more than 53% and 64%, respectively. A glut of cannabis and falling revenues were the most obvious reasons fo...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this event. For further details see: Jazz Pharmaceuticals (JAZZ) Presents At 41st Annual Healthcare Conference - Slideshow

Jazz Pharma ( NASDAQ: JAZZ ) and Zymeworks ( NASDAQ: ZYME ) announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial testing zanidatamab in combination with chemotherapy, in first-line patients with HER2-expressing metastatic...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) and Zymeworks ( NASDAQ: ZYME ) said Thursday that zanidatamab, an experimental therapy for gastroesophageal adenocarcinoma, indicated an 84% overall survival (OS) at 18 months as a first-line option with chemotherapy. The companies announc...

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma PR Newswire Results presented today at ASCO GI include first overall survival (OS) data...

Summary After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark.​ Additionally, the company secured non-dilutive capital to help initial commercialization efforts. While the market for Pedmark is limited, its critical use in the preve...

In 2022, the stock market had its worst year since the financial crisis in 2008. The S&P 500 declined 19.4%, and many industries were rocked due to inflation, supply chain, and many other issues. But two stocks that were able to prevail and deliver positive, double-digit returns include ...

Summary Floating-rate fixed-income securities should hold their value better than traditional bonds during periods of rising interest rates. Nuveen Floating Rate Income Fund invests primarily in a portfolio of these securities, so it should be a reasonably good choice for income in toda...

Summary Today, we circle back on Zymeworks Inc. and update our analysis to account for recent events. A recent license agreement has left the company flush with cash as it continues to advance its lead candidate. An investment analysis follows in the paragraphs below. ...